[5] In 2011, he was named CEO to drug manufacturer Patheon, based in Durham, North Carolina, as well as to their board.
Mullen has a Bachelor of Science in chemical engineering from Rensselaer Polytechnic Institute and a Master of Business Administration from Villanova University.
In a May proxy filing, Carl Icahn noted that Mullen was paid $60.8 million in total compensation, combining salary, bonus, and stock options over the preceding five years, while Biogen’s stock declined from $66.61 to $47.63 [40% in value] in that time."
Tysabri was "quickly pulled from the market after it was linked to a life-threatening brain infection in a handful of patients".
This led to Carl Icahn, an activist investor, demanding changes as he tried to gain more control over the board.